SAB Biotherapeutics, Inc. (SABS) — Dilution Risk Analysis

Current Snapshot

SAB Biotherapeutics, Inc. (SABS) has a DilutionWatch score of 55/10 and is classified as HIGH risk. The score date in the source data is 2026-10-03T03:45:52.527348.

This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.

Share Structure

Shares Outstanding
90,986,368 Source
Public Float
52,343,496 Source
Float as % of Outstanding
57.5%

Dilution Risk Score

Score: 55/10 Source (as of 2026-10-03T03:45:52.527348)

Recent SEC Filings

2 shelf registration or ATM offering filings detected in recent history.

Recent filing forms in the source payload: XBRL 1, 4 5, 424B5 2, 8-K 2.

FormFiledAccession
xbrl 2026-03-31 xbrl-5064-xbrl_warrant
4 2026-03-25 0001193125-26-124231
424B5 2026-03-19 0001193125-26-114728
8-K 2026-03-19 0001193125-26-114730
424B5 2026-03-17 0001193125-26-110666
8-K 2026-03-10 0001193125-26-099376
4 2026-02-05 0001193125-26-039508
4 2026-02-05 0001193125-26-039524
4 2026-02-05 0001193125-26-039537
4 2026-02-05 0001193125-26-039564

Dilution Risk Drivers

DriverStored ValueSource
ATM offering capacity remaining $75,000,000 Source
Cash runway 35 months Source
Three-year share count growth 769.53% Source

DilutionWatch Analysis

Risk Level
HIGH (Score: 55/10) Source
Cash Runway
35 months Source
ATM Offering Capacity Remaining
$75,000,000 Source
Share Count Growth (3-Year)
769.53% Source

What This Page Does Not Estimate

DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.

Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.